Cargando…
Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
PURPOSE: Wrist fractures are common, contribute significantly to morbidity in women with postmenopausal osteoporosis, and occur predominantly at the ultradistal radius, a site rich in trabecular bone. This exploratory analysis of the phase 3 ACTIVE study evaluated effects of abaloparatide versus pla...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546661/ https://www.ncbi.nlm.nih.gov/pubmed/30899994 http://dx.doi.org/10.1007/s00198-019-04890-2 |
_version_ | 1783423547882864640 |
---|---|
author | Watts, N.B. Hattersley, G. Fitzpatrick, L.A. Wang, Y. Williams, G.C. Miller, P.D. Cosman, F. |
author_facet | Watts, N.B. Hattersley, G. Fitzpatrick, L.A. Wang, Y. Williams, G.C. Miller, P.D. Cosman, F. |
author_sort | Watts, N.B. |
collection | PubMed |
description | PURPOSE: Wrist fractures are common, contribute significantly to morbidity in women with postmenopausal osteoporosis, and occur predominantly at the ultradistal radius, a site rich in trabecular bone. This exploratory analysis of the phase 3 ACTIVE study evaluated effects of abaloparatide versus placebo and teriparatide on forearm bone mineral density (BMD) and risk of wrist fracture. METHODS: Forearm BMD was measured by dual energy X-ray absorptiometry in a subset of 982 women from ACTIVE, evenly distributed across the three treatment groups. Wrist fractures were ascertained in the total cohort (N = 2463). RESULTS: After 18 months, ultradistal radius BMD changes from baseline were 2.25 percentage points greater for abaloparatide compared with placebo (95% confidence interval (CI) 1.38, 3.12, p < 0.001) and 1.54 percentage points greater for abaloparatide compared with teriparatide (95% CI 0.64, 2.45, p < 0.001). At 18 months, 1/3 radius BMD losses (versus baseline) were similar for abaloparatide compared with placebo (−0.42; 95% CI −1.03, 0.20; p = 0.19) but losses with teriparatide exceeded those of placebo (−1.66%; 95% CI −2.27, −1.06; p < 0.001). The decline with abaloparatide was less than that seen with teriparatide (group difference 1.22%; 95% CI 0.57, 1.87; p < 0.001). The radius BMD findings, at both ultradistal and 1/3 sites, are consistent with the numerically lower incidence of wrist fractures observed in women treated with abaloparatide compared with teriparatide (HR = 0.43; 95% CI 0.18, 1.03; p = 0.052) and placebo (HR = 0.49, 95% CI 0.20, 1.19, p = 0.11). CONCLUSIONS: Compared with teriparatide, abaloparatide increased BMD at the ultradistal radius (primarily trabecular bone) and decreased BMD to a lesser extent at the 1/3 radius (primarily cortical bone), likely contributing to the numerically lower wrist fracture incidence observed with abaloparatide. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-019-04890-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6546661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer London |
record_format | MEDLINE/PubMed |
spelling | pubmed-65466612019-06-19 Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis Watts, N.B. Hattersley, G. Fitzpatrick, L.A. Wang, Y. Williams, G.C. Miller, P.D. Cosman, F. Osteoporos Int Original Article PURPOSE: Wrist fractures are common, contribute significantly to morbidity in women with postmenopausal osteoporosis, and occur predominantly at the ultradistal radius, a site rich in trabecular bone. This exploratory analysis of the phase 3 ACTIVE study evaluated effects of abaloparatide versus placebo and teriparatide on forearm bone mineral density (BMD) and risk of wrist fracture. METHODS: Forearm BMD was measured by dual energy X-ray absorptiometry in a subset of 982 women from ACTIVE, evenly distributed across the three treatment groups. Wrist fractures were ascertained in the total cohort (N = 2463). RESULTS: After 18 months, ultradistal radius BMD changes from baseline were 2.25 percentage points greater for abaloparatide compared with placebo (95% confidence interval (CI) 1.38, 3.12, p < 0.001) and 1.54 percentage points greater for abaloparatide compared with teriparatide (95% CI 0.64, 2.45, p < 0.001). At 18 months, 1/3 radius BMD losses (versus baseline) were similar for abaloparatide compared with placebo (−0.42; 95% CI −1.03, 0.20; p = 0.19) but losses with teriparatide exceeded those of placebo (−1.66%; 95% CI −2.27, −1.06; p < 0.001). The decline with abaloparatide was less than that seen with teriparatide (group difference 1.22%; 95% CI 0.57, 1.87; p < 0.001). The radius BMD findings, at both ultradistal and 1/3 sites, are consistent with the numerically lower incidence of wrist fractures observed in women treated with abaloparatide compared with teriparatide (HR = 0.43; 95% CI 0.18, 1.03; p = 0.052) and placebo (HR = 0.49, 95% CI 0.20, 1.19, p = 0.11). CONCLUSIONS: Compared with teriparatide, abaloparatide increased BMD at the ultradistal radius (primarily trabecular bone) and decreased BMD to a lesser extent at the 1/3 radius (primarily cortical bone), likely contributing to the numerically lower wrist fracture incidence observed with abaloparatide. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-019-04890-2) contains supplementary material, which is available to authorized users. Springer London 2019-03-21 2019 /pmc/articles/PMC6546661/ /pubmed/30899994 http://dx.doi.org/10.1007/s00198-019-04890-2 Text en © The Author(s) 2019 OpenAccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Watts, N.B. Hattersley, G. Fitzpatrick, L.A. Wang, Y. Williams, G.C. Miller, P.D. Cosman, F. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis |
title | Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis |
title_full | Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis |
title_fullStr | Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis |
title_full_unstemmed | Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis |
title_short | Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis |
title_sort | abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546661/ https://www.ncbi.nlm.nih.gov/pubmed/30899994 http://dx.doi.org/10.1007/s00198-019-04890-2 |
work_keys_str_mv | AT wattsnb abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis AT hattersleyg abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis AT fitzpatrickla abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis AT wangy abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis AT williamsgc abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis AT millerpd abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis AT cosmanf abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis |